<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2012-8-6-766-771</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-630</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>ASSESSMENT OF DIABETES RISK IN MEN WITH DIFFERENT LEVELS OF CARDIOVASCULAR RISK</article-title><trans-title-group xml:lang="ru"><trans-title>ОЦЕНКА РИСКА РАЗВИТИЯ САХАРНОГО ДИАБЕТА У МУЖЧИН С РАЗЛИЧНЫМ УРОВНЕМ СЕРДЕЧНО-СОСУДИСТОГО РИСКА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковригина</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovrigina</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>м.н.с. лаборатории оценки и коррекции сердечно-сосудистого риска хронических неинфекционных заболеваний (ХНИЗ) отдела эпидемиологии</p></bio><email xlink:type="simple">Mkovrigina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамедов</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamedov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, руководитель лаборатории оценки и коррекции сердечно-сосудистого риска хронических неинфекционных заболеваний (ХНИЗ) отдела эпидемиологии</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Center for Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2016</year></pub-date><volume>8</volume><issue>6</issue><fpage>766</fpage><lpage>771</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kovrigina M.N., Mamedov M.N., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Ковригина М.Н., Мамедов М.Н.</copyright-holder><copyright-holder xml:lang="en">Kovrigina M.N., Mamedov M.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/630">https://www.rpcardio.online/jour/article/view/630</self-uri><abstract><p>Aim. To assess the risk of diabetes mellitus type 2 (DM2) in patients with various cardiovascular (CV) risk, and to identify the relationship between a high risk of DM2 and the major CV risk factors. Material and methods. Men (n=378) with one or more CV risk factors (hypertension of stage 1–3, smoking, hypercholesterolemia) and various CV risk (SCORE) were included in the one- stage clinical trial. All patients were interviewed with standard questionnaire and FINDRISC questionnaire, as well as glucose tolerance test was performed. Results. The patients were split into three groups based on the total CV risk (SCORE): 33.6% had low-to-moderate CV risk, 38.9% — high CV risk and 27.5% — very high CV risk. Most of the men were in the 50–59 and 60–69 years age groups. Most of the patients aged 40–49 years had the high CV risk, while 59% of men aged 50–59 had moderate CV risk. Every second older male had a very high CV risk. According to the FINDRISC questionnaire low risk of DM2 in the next 10 years was detected in 40.2% of patients, intermediate risk — in 35.2%, moderate risk — in 10.3%, high risk — in 11.1%, a very high risk — in 3.2% of patients. Conclusion. Men with very high CV risk (SCORE) have also high and very high risk of DM2 (according to FINDRISC questionnaire). Detection of early markers of glucose metabolism disturbances as well as DM2 risk assessment should be performed in patients with one or more of the above mentioned CV risk factors. This strategy is able to contribute to proper DM2 risk assessment and development of methods of DM2 prevention.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Оценить риск развития сахарного диабета 2 типа (СД2) у пациентов с различным риском сердечно-сосудистых (CC) осложнений, а также выявить связь между высоким уровнем риска СД2 и основными факторами СС риска. Материал и методы. В одномоментное клиническое исследование были включены 378 мужчин с наличием одного и более CC факторов риска (артериальная гипертония 1–3 ст., курение, гиперхолестеринемия) и различным уровнем CC риска по шкале SCORE. Все пациенты были опрошены по стандартной анкете и опроснику FINDRISC, был проведен тест толерантности к глюкозе. Результаты. Пациенты были распределены на три группы по уровню суммарного CC риска по SCORE: 33,6% имели низкий/умеренный CC риск, 38,9% — высокий и 27,5% — очень высокий CC риск. Большинство мужчин оказались в возрастных группах 50–59 и 60–69 лет. В возрастной группе 40–49 лет большинство пациентов имели высокий CC риск, тогда как у 59% мужчин в возрасте 50–59 лет выявлен умеренный CC риск. У каждого второго мужчины старшего возраста выявляется очень высокий CC риск. По результатам опроса по опроснику FINDRISC у 40,2% выявлен низкий риск развития СД2 в ближайшие 10 лет , у 35,2% — промежуточный риск, у 10,3% — умеренный риск, высокий риск выявлен у 11,1% пациентов, а очень высокий риск определен у 3,2% пациентов. Заключение. У лиц с очень высоким CC риском по шкале SCORE также имеется высокий и очень высокий риск развития СД2 по опроснику FINDRISC. Среди пациентов с наличием одного и более вышеуказанных CC факторов риска необходимо выявлять ранние маркеры нарушений углеводного обмена и оценивать риск развития СД2. Подобная тактика способствует адекватной оценке риска СД2 и разработке методов его профилактики.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ранние нарушения углеводного обмена</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>сахарный диабет 2 типа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>early glucose metabolism disturbances</kwd><kwd>cardiovascular diseases</kwd><kwd>diabetes mellitus 2 type</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cardiovascular diseases. Fact sheet number 317. September 2012. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed on 10/06/2012.</mixed-citation><mixed-citation xml:lang="en">Cardiovascular diseases. Fact sheet number 317. September 2012. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed on 10/06/2012.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 1–64 Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная Терапия и Профилактика 2011; 10 (6) Приложение 2: 1–64</mixed-citation><mixed-citation xml:lang="en">National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 1–64 Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная Терапия и Профилактика 2011; 10 (6) Приложение 2: 1–64</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bonora E, Targher G, Formentini G et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21(1):52–8.</mixed-citation><mixed-citation xml:lang="en">Bonora E, Targher G, Formentini G et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21(1):52–8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mamedov M.N., Poddubskaya E.A. Early diagnosis and treatment of disorders of glucose metabolism in the therapeutic practice (guidelines). Moscow: GNITs PM; 2011. Russian (Мамедов М.Н., Поддубская Е.А. Диагностика и лечение ранних нарушений углеводного обмена в общетерапевтической практике (методические рекомендации). М.: ГНИЦ ПМ; 2011).</mixed-citation><mixed-citation xml:lang="en">Mamedov M.N., Poddubskaya E.A. Early diagnosis and treatment of disorders of glucose metabolism in the therapeutic practice (guidelines). Moscow: GNITs PM; 2011. Russian (Мамедов М.Н., Поддубская Е.А. Диагностика и лечение ранних нарушений углеводного обмена в общетерапевтической практике (методические рекомендации). М.: ГНИЦ ПМ; 2011).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kahn C.R. Diabetes. Causes of insulin resistance. Nature 1995;373(6513):384–5.</mixed-citation><mixed-citation xml:lang="en">Kahn C.R. Diabetes. Causes of insulin resistance. Nature 1995;373(6513):384–5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">National guidelines for the diagnosis and treatment of metabolic syndrome. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6(6) suppl 2: 1–26. Russian (Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваскулярная Терапия и Профилактика 2007; 6(6) приложение 2: 1–26).</mixed-citation><mixed-citation xml:lang="en">National guidelines for the diagnosis and treatment of metabolic syndrome. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6(6) suppl 2: 1–26. Russian (Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваскулярная Терапия и Профилактика 2007; 6(6) приложение 2: 1–26).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 2007; 9 (suppl C): C3–C74.</mixed-citation><mixed-citation xml:lang="en">Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 2007; 9 (suppl C): C3–C74.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bozorgmanesh M, Hadaegh F, Sheikholeslami F et al. Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. Cardiovasc Diabetol 2012;11:69.</mixed-citation><mixed-citation xml:lang="en">Bozorgmanesh M, Hadaegh F, Sheikholeslami F et al. Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. Cardiovasc Diabetol 2012;11:69.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Toeller M, Buyken AE, Heitkamp G Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. Diabetes Care 1999;22 Suppl 2:B21–8.</mixed-citation><mixed-citation xml:lang="en">Toeller M, Buyken AE, Heitkamp G Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. Diabetes Care 1999;22 Suppl 2:B21–8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglaemia and newly-diagnosed diabetes. Diabetologia 2003; 46: 608–17.</mixed-citation><mixed-citation xml:lang="en">The DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglaemia and newly-diagnosed diabetes. Diabetologia 2003; 46: 608–17.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Daly CA, Clemens F, Sendon JL, et al.; Euro Heart Survey Investigators. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26(10):1011–22.</mixed-citation><mixed-citation xml:lang="en">Daly CA, Clemens F, Sendon JL, et al.; Euro Heart Survey Investigators. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26(10):1011–22.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Schwarz P.E., Li J., Reimann M., et al. The Finnish Diabetes Risk Score Is Associated with Insulin Resistance and Progression towards Type 2 Diabetes. J Clin Endocrinol Metab 2009;94(3):920–926.</mixed-citation><mixed-citation xml:lang="en">Schwarz P.E., Li J., Reimann M., et al. The Finnish Diabetes Risk Score Is Associated with Insulin Resistance and Progression towards Type 2 Diabetes. J Clin Endocrinol Metab 2009;94(3):920–926.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">The DECODE (Тhe Diabetes Epidemiology: Collaborative Analysis of Diagnostic Critera in Europe) Study Group. Glugose tolerance and mortality: comparison off WHO and ADA diagnostic criteria. Lancet 1999; 354: 617–621.</mixed-citation><mixed-citation xml:lang="en">The DECODE (Тhe Diabetes Epidemiology: Collaborative Analysis of Diagnostic Critera in Europe) Study Group. Glugose tolerance and mortality: comparison off WHO and ADA diagnostic criteria. Lancet 1999; 354: 617–621.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
